Published on 29/11/2025

COI/COC Deviations: CAPA and Effectiveness

This tutorial provides a comprehensive step-by-step guide for pharmaceutical professionals focused on Chain-of-Identity (COI) and Chain-of-Custody (COC) deviations, highlighting the importance of Corrective and Preventive Actions (CAPA) and effectiveness in the context of viral clearance validation, particularly in biologics, Advanced Therapy Medicinal Products (ATMP), and their associated complex critical quality attributes (CQAs).

Understanding COI and COC in the Biologics Sector

Chain-of-Identity and Chain-of-Custody are critical concepts in the biologics and ATMP field, essential to guarantee the integrity, quality, and safety of products from development through to commercialization. COI ensures that the biological material (such as cells, tissues, or vectors) received, manipulated, and utilized are precisely those intended for research or production, while COC relates to the management of the materials throughout their lifecycle, ensuring they are correctly tracked from collection to administration in patients.

In the US, compliance with these principles is a requirement laid out by regulatory bodies, including the FDA, and similarly, the EMA and MHRA have established guidelines that focus on ensuring these chains are effectively maintained and documented. Deviations from established protocols can lead to significant implications for patient safety and regulatory compliance. Below is a structured approach for understanding and addressing COI/COC deviations.

Components of COI and COC Systems

• Documentation: Maintaining accurate records of every step in the chain, including donor information, tracking, handling, and testing results.
• Training: Ensuring that all personnel are adequately trained on the COI/COC policies relevant to their roles.
• Traceability: Implementing systems to track all materials throughout their lifecycle.
• Compliance Monitoring: Regular audits and reviews of procedures to ensure compliance with regulations such as ICH Q5A(R2).

Identifying COI/COC Deviations

Identifying deviations in the COI and COC processes is vital for maintaining compliance and ensuring product integrity. Deviations can occur at any point in the process and may include:

• Inadequate documentation leading to poor traceability of biological materials.
• Failure to train staff adequately, resulting in non-compliance with procedures.
• Physical breaches of the closed systems designed to maintain sterility and integrity of biologic products.
• Issues arising from spiking studies that do not align with established protocols.

Regulatory agencies expect thorough investigation and resolution of such deviations, as they could compromise product safety or efficacy. Professionals must develop robust deviation reporting systems that incorporate thorough documentation of the detected issues, root cause analysis, and effective CAPA implementation.

Utilizing CAPA in Response to Deviations

The CAPA process is critical for addressing and preventing the recurrence of COI/COC deviations. Successful CAPA resolution requires a structured approach encompassing:

• Corrective Actions: Immediate actions taken to rectify the identified issue.
• Preventive Actions: Steps implemented to prevent the recurrence of the deviation.
• Verification and Effectiveness Check: Ensuring that the corrective and preventive measures were effective.

When initiating a CAPA, it is essential to first identify the root causes of the COI/COC deviation through methodologies such as the 5 Whys or fishbone diagrams. Following this analysis, documentation of all corrective and preventive actions taken should be rigorous, with attention given to involved workflows and impacted personnel.

Effectiveness of CAPA Measures

After implementing CAPA measures, practices must include effective monitoring mechanisms to validate their success. This can be achieved through:

• Trend Analysis: Reviewing data trends post-CAPA implementation to assess the impact.
• Audit Readiness: Preparing for internal and external audits by ensuring all documentation and systems are in place.
• Regular Updates: Continually updating training programs based on findings from deviations.

It is also worthwhile to integrate effectiveness evaluations into the ongoing quality management systems (QMS). This approach allows organizations to proactively identify any new deviations or weaknesses in the COI/COC processes, thereby supporting long-term compliance and safety objectives.

Spiking Studies and Their Relevance to COI/COC

Spiking studies are often employed to examine the efficacy of viral clearance validation processes within biologic manufacturing, thereby establishing the robustness of their processes. Understanding how deviations in COI/COC affect these studies is crucial, as they can critically influence patient safety outcomes. For instance, the introduction of adventitious agents during a spiking study could result from lapses in the COI and COC protocols.

The importance of maintaining closed systems and single-use systems cannot be overstated here. Their designs aim to minimize any exposure and contamination risk during the handling of biologic materials, thus supporting stringent aseptic controls. These systems should be regularly evaluated and tailored according to the specific requirements established by product-specific protocols and ICH guidelines.

Implementing Closed and Single-Use Systems

• Design Considerations: Closed systems must be designed to ensure integrity and sterility throughout the lifecycle of biologics. Single-use systems offer a practical solution to reduce the risk of cross-contamination.
• Validation: Comprehensive validation protocols must be established to confirm that these systems function under all anticipated conditions.
• Training and Compliance: All personnel must be trained regarding the correct use and handling of these systems.

Conclusion: Strengthening COI and COC Processes

The need for stringent COI/COC management in the pharmaceutical sector, especially concerning biologics and ATMPs, is paramount. By effectively implementing control measures, establishing robust CAPA processes, and rigorously evaluating efficacy, pharmaceutical organizations can mitigate risks, enhance patient safety, and maintain compliance with regulatory standards.

Through this structured approach to validating viral clearance via effective COI/COC management, professionals within the pharmaceutical field can not only ensure the integrity of their biological products but also fortify the trust stakeholders have in their processes. This culminates in a more robust quality management framework that aligns with both regulatory expectations and patient safety objectives.